Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Neurotoxin Type A Free Of Complexing Proteins (XEOMIN®) In Focal Dystonia

W. Jost, Joerg Bluemel, S. Grafe
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to be effective in a wide range of other indications, such as gastrointestinal disorders, hyperhidrosis and cosmetic wrinkle correction (e.g. glabellar frown lines). A new formulation of BTX-A, NT 201 (XEOMIN®) has been developed. NT 201 is a formulation of pure BTX-A free of complexing proteins and, therefore, may have a reduced immunogenic potential compared with other BTX-A preparations. The pre-clinical and clinical development of NT 201 is reviewed in this article.A total of five clinical trials were completed in Europe and Israel. Two studies were conducted in 46 healthy volunteers. A further three studies in 816 patients were conducted to provide data on the safety and efficacy of NT 201 in the treatment of CD and BEB. NT 201 was found to provide non-inferior efficacy and safety profiles in the treatment of CD and BEB compared with a BTX-A preparation containing complexing proteins (BOT [BOTOX®]). The clinical development programme of NT 201 showed a 1 : 1 NT 201 to BOT dose ratio. The pre-clinical studies conducted with NT 201 showed an acceptable safety profile and support the use of NT 201 in an intramuscular administration regimen for patients with CD and BEB. NT 201 was effective, well tolerated and non-inferior to BOT in the treatment of both CD and BEB. In addition, there were no differences between the two therapies in terms of onset of action, duration and waning of effect. Further research is required to determine the long-term efficacy and safety profile of NT 201.
This paper references
Botulinum toxin ences on the frequency and age of onset of primary dystonia. therapy, immunologic resistance, and problems with available
G Borodic (1996)
Telemetry as a tool to linum toxin
W Huang
Botulinum toxin type 21. Wohlfarth K, Mueller C. Safety, efficacy, and duration of effect A therapy for blepharospasm. Cochrane Database Syst Rev of a new botulinum neurotoxin type A preparation free
J Costa (2004)
10.1002/14651858.cd003633.pub2
Botulinum toxin type A therapy for cervical dystonia.
J. Costa (2005)
Evidence - based medicine : botulinum toxin in assay for Clostridium botulinum neurotoxins
EJ Schantz (2001)
Duration of effect ofdose - effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia
AS Buchman (1994)
10.1212/wnl.53.8.1871
Sex-related influences on the frequency and age of onset of primary dystonia
T. Warner (1999)
10.1016/S0733-8635(02)00043-8
Update on botulinum toxin for facial aesthetics.
J. Cather (2002)
10.1007/s00702-005-0323-3
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
P. Roggenkaemper (2005)
evaluate simultaneously the efficacy and safety of a neuromuscular blocking agent in the monkey
S Milano
10.3109/9780203450321-49
Therapy with botulinum toxin
J. Jankovic (1994)
An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years.
A. G. Butler (2004)
Effects of aminoglycoside with repeated intramuscular administrations in the cynomolgus antibiotics on the neuromuscular junction: part I
S Yamada (1986)
New York: Marcel Dekker, 1994: botulinum toxin serotypes A and B for the treatment of cervi-211-37 cal dystonia
C L Comella
The role of botulinum toxin in gastrointestinal disorders
G Brisinda (2002)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
Clinical assessments of patients with
E S Consky
10.1097/01.PRS.0000144795.76040.D3
Consensus recommendations on the use of botulinum toxin type a in facial aesthetics.
J. Carruthers (2004)
Physiology of dystonia.
M. Hallett (1998)
Botulinum toxin in the S 11 treatment of writer ’ s cramp : a double - blind study
JK Tsui
Comparison of efficacy and ization Holder for NT 201 in Germany . immunogenicity of original versus current botulinum toxin in cervical dystonia
J Jankovic (2003)
Efficacy and safety of botulinum toxin for the treatment of wrist and finger spastic - of a new botulinum toxin type A free of complexing proteins in ity after a stroke
A Brashear (2002)
therapy: neutralizing and nonneutralizing antibodies -thera-46. Walts LF. Neuromuscular blocking drugs. Otolaryngol Clin peutic consequences
H Göschel
Blepharospasm and hemifacial spasm
T. Square (2004)
10.1128/AEM.48.5.951-955.1984
Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism.
Y. Wang (1984)
10.1007/S11940-000-0037-7
Blepharospasm and hemifacial spasm
D. Boghen (2000)
A new botulinum toxin double - blind , placebo - controlled study
R Benecke (2006)
Microbiological methods: standardized
E J Schantz
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke.
A. Jahangir (2007)
10.1212/01.wnl.0000183055.81056.5c
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
C. Comella (2005)
; botulinum toxin type A in adult patients with cervical dystonia : 17 ( 2 ) : 188 - 95 a retrospective chart review
ES Consky (2000)
10.1212/WNL.46.1.26
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G. Borodic (1996)
10.2165/00003495-200464030-00002
Primary Blepharospasm
G. Defazio (2012)
The Blepharospasm Disability Index ( BSDI ) : reliability and validity
J Jankovic (2006)
10.1212/01.WNL.0000163767.99354.C3
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R. Benecke (2005)
The interaction between aminoquinolines and presynaptically acting neurotoxins.
L. Simpson (1982)
Comparison ofwith botulinum toxin . New York : Marcel Dekker , 1994 : botulinum toxin serotypes A and B for the treatment of cervi - 211 - 37 cal dystonia
J Jankovic (2005)
10.1097/00001503-199208000-00029
Neuromuscular blocking drugs.
Walts Lf (1981)
Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations.
J. I. Santos (1981)
10.1099/MIC.0.28421-0
Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin.
J. Lee (2005)
Consensus recommenda-27. Merz Pharmaceuticals GmbH. Oral toxicity of NT-101 in CD-1 tions on the use of botulinum toxin type a in facial aesthetics. mice. Frankfurt: Merz Pharmaceuticals GmbH
J Carruthers (2000)
Botulinum toxin: from poison to remedy.
K. R. Kessler (1997)
The role of botu
G Brisinda
Dystonia: etiology, clinical features, and treatment. Philadelphia (PA): Lippincott 30
M F Brin (2004)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
Hemagglutinin binding mediated protec
S K Sharma
Primary blepharospasm : diagnosis and 1987 ; 37 ( 4 ) : 616 - 23 management
R Goertelmeyer
Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics : clinical and labo - Neurology and Clinical Neurophysiology , Deutsche Klinik ratory observations
YC Wang (1981)
10.1097/00002826-199404000-00008
Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia
A. Buchman (1994)
10.1007/BF03033933
Botulinum toxin therapy for cervical dystonia
J. Jankovic (2009)
Identification and charac - aesthetics
Y Fujinaga (2002)
a retrospective chart review
An epidemiologic A progenitor neurotoxin involved in binding to intestinalsurvey of dystonia within the entire population of northeast microvilli and erythrocytes
AG Butler (2000)
Simpson LL. The interaction between aminoquinolines and Toxicol
(2005)
[Treatment of cervical dystonia with botulinum toxin].
N. Gouider-Khouja (1999)
Production of anti - neurotoxin antibody is enhanced by two subcomponents , HA 1 Acknowledgements and HA 3 b , of Clostridium botulinum type B 16 S toxin - haemagglutinin
JC Lee (2005)
10.1016/S0149-2918(00)83049-0
Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.
A. Brashear (2000)
10.1006/exnr.1997.6580
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
H. Göschel (1997)
Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis.
S. Sharma (1998)
10.1212/WNL.43.1_Part_1.183
Botulinum toxin in the treatment of writer's cramp
J. Tsui (1993)
Botulinum toxinences on the frequency and age of onset of primary dystonia . therapy , immunologic resistance , and problems with availableNeurology 1999 Nov ; 53 ( 8 ) : 1871 - 3 materials
RL Anderson (1996)
Neuromuscular blocking drugs . Otolaryngol Clinpeutic consequences
LF Walts (1997)
No spread of a new 1993 ; 43 ( 1 ) : 1835 botulinum neurotoxin type A preparation in adjacent muscles
K Wohlfarth
Effects of aminoglycoside antibiotics on the neuromuscular junction: Part I.
S. Yamada (1986)
10.1007/PL00007817
Evidence-based medicine: botulinum toxin in focal hyperhidrosis
M. Naumann (2001)
A new botulinum toxin double-blind, placebo-controlled study. Dev Med Child type A free of complexing proteins for treatment of cervical Neurol
V Mall (2005)
Evidence-based medicine: botulinum toxin in assay for Clostridium botulinum neurotoxins. J Assoc Off Anal focal hyperhidrosis
M Naumann (1978)
10.1212/01.WNL.0000027361.73814.0E
Blepharospasm: recent advances.
M. Hallett (2002)
10.1007/978-3-642-59567-7_15
Botulinum toxin.
V. Mall (1990)
10.1002/14651858.CD004900.PUB2
Botulinum toxin type A therapy for blepharospasm.
J. Costa (2005)
Clinical assessments of patients with 1516 - 24 cervical dystonia
J Jankovic
Comelpasm Disability Index (BSDI) for the assessment of functional la C, Jankovic J, editors. Dystonia: etiology, clinical features, health in focal dystonia
R Goertelmeyer (2002)
linum toxin in gastrointestinal disorders
Dystonia: etiology, clinical features, and treatment
J BlepharospasmKingChingTsui (2004)
10.1007/s00702-004-0234-8
Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteers
W. Jost (2004)
10.1017/S0012162206000041
Treatment of adductor spasticity with BTX‐A in children with CP: a randomized, double‐blind, placebo‐controlled study
V. Mall (2006)
10.1097/00002341-199809000-00002
Blepharospasm: Past, Present, and Future
R. Anderson (1998)
Botulinum toxin type ( NT 201 ) compared with commercially available botulinum A therapy for cervical dystonia . Cochrane Database Syst Rev toxin type A ( BOTOX ® ) in healthy volunteers
WH Jost (2005)
10.1212/01.WNL.0000055087.96356.BB
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
J. Jankovic (2003)
Botulinum toxin : from poison to reme - addition , there were no differences between the two dy
KR Kessler (1997)
Update on botulinum toxin for facial 28
JC Cather
10.1016/S0014-5793(00)01147-9
Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes
Y. Fujinaga (2000)
10.1073/PNAS.96.6.3200
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
A. de Paiva (1999)



This paper is referenced by
10.3109/9781841848525-29
Botulinum toxins in the treatment of dystonia
Mark Stacy (2012)
Botulinum Toxin : Formulation, Concentration and Treatment
Alma Rystedt (2012)
10.1016/J.NEUROL.2009.09.004
La neurotoxine botulinique
B. Poulain (2010)
10.1007/978-3-642-12915-5_40
Parkinsonkrankheit und Dystonie
Georg Ebersbach (2010)
10.1016/j.jns.2015.01.033
Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke
A. Santamato (2015)
10.1007/s00415-016-8050-2
A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia
Y. Han (2016)
10.1002/9781118661833.CH1
History of Botulinum Toxin for Medical and Aesthetic Use
Alastair Carruthers (2017)
Botulinum toxin: Bioweapon & magic drug
R. K. Dhaked (2010)
10.2147/DDDT.S79193
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
W. Jost (2015)
10.5772/53882
Office – Based Facial Cosmetic Procedures
Farzin Sarkarat (2013)
10.1007/978-1-4939-0261-3_2
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
A. Pickett (2014)
Correction of dynamic wrinkles with incobotulinumtoxinA
N. Cymbalista (2012)
10.1007/978-3-319-61724-4_9
Non-cosmetic Botulinum Toxin Treatments in the Head and Neck
L. Madden (2018)
10.1007/s40268-015-0086-8
‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’
W. Jost (2015)
10.1002/9781118661833.CH11
Treatment of the Forehead
Joel L Cohen (2017)
10.2147/BTT.S65603
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
12 Botulism and Tetanus
M. Popoff (2013)
10.1002/9781118661833.CH6
IncobotulinumtoxinA (Xeomin®/Bocouture®)
Ulrich Kühne (2017)
10.3390/toxins10120535
AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
Malgorzata Field (2018)
10.3109/02699052.2011.613085
Early use of Xeomin neurotoxin for local anti-spasticity therapy for pes equines after acquired brain injury (ABI)
M Lippert-Gruner (2011)
10.2340/16501977-1895
Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
D. Grosset (2015)
10.14704/NQ.2019.17.3.2010
Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA
M. Tomaselli (2019)
10.1016/B978-0-444-52014-2.00037-9
Adult-onset dystonia.
M. Evatt (2011)
10.1016/j.ejpn.2016.04.008
Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
E. Carraro (2016)
10.1007/978-1-4939-0261-3
Clinical Applications of Botulinum Neurotoxin
K. Foster (2014)
10.2340/00015555-1606
Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study.
A. Rystedt (2013)
10.1093/asj/sju105
Report of Allergic Reaction After Application of Botulinum Toxin.
Mariana Figueiroa Careta (2015)
10.2147/OPTH.S13978
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
J. Park (2011)
10.1177/1756286419892078
Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
H. Hefter (2019)
10.1007/978-1-4614-4466-4
Craniofacial Muscles
L. McLoon (2013)
Following the advent of Botulinum toxin : Bioweapon & magic drug
R. K. Dhaked (2010)
10.1007/s10286-015-0278-x
Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics
Anna Karlsson-Groth (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar